相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。THE SHOWSTOPPER OBESITY DRUGS THAT HAVE STUNNED RESEARCHERS
McKenzie Prillaman
NATURE (2023)
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist
Olivier Benichou et al.
CELL METABOLISM (2023)
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart et al.
CELL METABOLISM (2022)
GIPR Is Predominantly Localized to Nonadipocyte Cell Types Within White Adipose Tissue
Jonathan E. Campbell et al.
DIABETES (2022)
Acute concomitant glucose-dependent insulinotropic polypeptide receptor antagonism during glucagon-like peptide 1 receptor agonism does not affect appetite, resting energy expenditure or food intake in patients with type 2 diabetes and overweight/obesity
Signe Stensen et al.
DIABETES OBESITY & METABOLISM (2022)
Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Victoria E. R. Parker et al.
DIABETES OBESITY & METABOLISM (2022)
Glucose-dependent insulinotropic polypeptide receptor antagonist treatment causes a reduction in weight gain in ovariectomised high fat diet-fed mice
Geke Aline Boer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems
Bin Yang et al.
MOLECULAR METABOLISM (2022)
What's preventing us from curbing the obesity crisis?
[Anonymous]
LANCET DIABETES & ENDOCRINOLOGY (2022)
Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss
David C. D. Hope et al.
CELL REPORTS MEDICINE (2022)
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coskun et al.
CELL METABOLISM (2022)
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Shweta Urva et al.
LANCET (2022)
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey et al.
NATURE MEDICINE (2022)
Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
David C. W. Lau et al.
LANCET (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Parsa Akbari et al.
SCIENCE (2021)
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Ricardo J. Samms et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Shu-Chen Lu et al.
CELL REPORTS MEDICINE (2021)
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
Natasha C. Bergmann et al.
DIABETES CARE (2020)
Disconnect between signalling potency and in vivo ef fi cacy of pharmacokinetically optimised biased glucagon-like peptide-1 receptor agonists
Maria Lucey et al.
MOLECULAR METABOLISM (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
Natasha C. Bergmann et al.
DIABETOLOGIA (2019)
GIP-induced vasodilation in human adipose tissue involves capillary recruitment
Meena Asmar et al.
ENDOCRINE CONNECTIONS (2019)
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
Alice E. Adriaenssens et al.
CELL METABOLISM (2019)
Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
Kentaro Kaneko et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Ben Jones et al.
NATURE COMMUNICATIONS (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus
Christophe Schmitt et al.
DIABETES OBESITY & METABOLISM (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis
Zin Z. Htike et al.
DIABETES OBESITY & METABOLISM (2017)
Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors
A. H. Sparre-Ulrich et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice
Shu Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2015)
GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial
Oezlem Goegebakan et al.
DIABETOLOGIA (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation
Chen Varol et al.
JOURNAL OF IMMUNOLOGY (2014)
Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes
Katharina Timper et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
Structural and Pharmacological Characterization of Novel Potent and Selective Monoclonal Antibody Antagonists of Glucose-dependent Insulinotropic Polypeptide Receptor
Peter Ravn et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
Su-Jin Kim et al.
PLOS ONE (2012)
Lateral Allosterism in the Glucagon Receptor Family: Glucagon-Like Peptide 1 Induces G-Protein-Coupled Receptor Heteromer Formation
Dominik Schelshorn et al.
MOLECULAR PHARMACOLOGY (2012)
Administration of an acylated GLP-I and GIP preparation provides added beneficial glucose-lowering and insulinotropic actions over single incretins in mice with Type 2 diabetes and obesity
Victor A. Gault et al.
CLINICAL SCIENCE (2011)
On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
Meena Asmar et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2010)
Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
Meena Asmar et al.
DIABETES (2010)
Antidiabetic effects of sub-chronic activation of the GIP receptor alone and in combination with background exendin-4 therapy in high fat fed mice
Nigel Irwin et al.
REGULATORY PEPTIDES (2009)
(Pro3) GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy
P. L. McClean et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
Daniel J. Drucker et al.
LANCET (2008)
Effects of bariatric surgery on mortality in Swedish obese subjects
Lars Sjostrom et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Activation of lipoprotein lipase by glucose-dependent insulinotropic polypeptide in adipocytes - A role for a protein kinase B, LKB1, and AMP-activated protein kinase cascade
Su-Jin Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K. Wynne et al.
INTERNATIONAL JOURNAL OF OBESITY (2006)
Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters
CW le Roux et al.
ANNALS OF SURGERY (2006)
Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig
A Plamboeck et al.
DIABETOLOGIA (2005)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)
分享论文
